Investigation of the Role of Healthy and Sick Equids in the COVID-19 Pandemic through Serological and Molecular Testing.

Kaila O Y Lawton1 Rick M Arthur2 Benjamin C Moeller3,4 Samantha Barnum1 Nicola Pusterla1
Affiliations 4 institutions
  1. Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, CA 95616, USA.
  2. School of Veterinary Medicine, University of California, Davis, CA 95616, USA.
  3. KL Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California, Davis, CA 95616, USA.
  4. Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA 95616, USA.

Abstract

More and more studies are reporting on the natural transmission of SARS-CoV-2 between humans with COVID-19 and their companion animals (dogs and cats). While horses are apparently susceptible to SARS-CoV-2 infection based on the homology between the human and the equine ACE-2 receptor, no clinical or subclinical infection has yet been reported in the equine species. To investigate the possible clinical role of SARS-CoV-2 in equids, nasal secretions from 667 horses with acute onset of fever and respiratory signs were tested for the presence of SARS-CoV-2 by qPCR. The samples were collected from January to December of 2020 and submitted to a commercial molecular diagnostic laboratory for the detection of common respiratory pathogens (equine influenza virus, equine herpesvirus-1/-4, equine rhinitis A and B virus, Streptococcus equi subspecies equi). An additional 633 serum samples were tested for antibodies to SARS-CoV-2 using an ELISA targeting the receptor-binding domain of the spike protein. The serum samples were collected from a cohort of 587 healthy racing Thoroughbreds in California after track personnel tested qPCR-positive for SARS-CoV-2. While 241/667 (36%) equids with fever and respiratory signs tested qPCR-positive for at least one of the common respiratory pathogens, not a single horse tested qPCR-positive for SARS-CoV-2. Amongst the racing Thoroughbreds, 35/587 (5.9%) horses had detectable antibodies to SARS-CoV-2. Similar to dogs and cats, horses do not seem to develop clinical SARS-CoV-2 infection. However, horses can act as incidental hosts and experience silent infection following spillover from humans with COVID-19. SARS-CoV-2-infected humans should avoid close contact with equids during the time of their illness.

Supporting text Virus Host Location
blood 3 ELISA 28 healthy horses 1 horses 53 nasal secretions 1 qPCR 2 SARS-CoV-2 550 sick equids 1

Evidence records

3 total
Zoonotic Surveillance
3 records · 2 evidence types
Evidence type
1 records
Evidence type
2 records
OVE5746
Key finding

Serological testing detected antibodies to SARS-CoV-2 in 5.9% of racing Thoroughbreds sampled in California.

Virus
Host
Location
Not specified
Supporting text

Amongst the racing Thoroughbreds, 35/587 (5.9%) horses had detectable antibodies to SARS-CoV-2.

Method
ELISA targeting the receptor-binding domain of the spike protein
Sample type
serum samples
OVE5747
Key finding

Seropositive racing Thoroughbreds were linked to exposure following SARS-CoV-2-positive human personnel, indicating possible human-to-horse spillback.

Virus
Host
Location
Supporting text

The serum samples were collected from a cohort of 587 healthy racing Thoroughbreds in California after track personnel tested qPCR-positive for SARS-CoV-2.

Method
qPCR testing of personnel | ELISA detection of antibodies in equine sera